<code id='4F7D439767'></code><style id='4F7D439767'></style>
    • <acronym id='4F7D439767'></acronym>
      <center id='4F7D439767'><center id='4F7D439767'><tfoot id='4F7D439767'></tfoot></center><abbr id='4F7D439767'><dir id='4F7D439767'><tfoot id='4F7D439767'></tfoot><noframes id='4F7D439767'>

    • <optgroup id='4F7D439767'><strike id='4F7D439767'><sup id='4F7D439767'></sup></strike><code id='4F7D439767'></code></optgroup>
        1. <b id='4F7D439767'><label id='4F7D439767'><select id='4F7D439767'><dt id='4F7D439767'><span id='4F7D439767'></span></dt></select></label></b><u id='4F7D439767'></u>
          <i id='4F7D439767'><strike id='4F7D439767'><tt id='4F7D439767'><pre id='4F7D439767'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:Wikipedia    Page View:746
          Adobe

          Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans — a crucial step toward quantifying the impact of therapies on a condition whose progress is notoriously difficult to measure objectively. And that’s thanks to generative AI, they say.

          In a small study published Wednesday — just 10 people with severe, treatment-resistant depression receiving deep brain stimulation therapy — researchers used the electrodes to record brain activity and later fed the scans into a homegrown artificial intelligence system that analyzed them for patterns. They found that it was possible to track patients’ recovery through changes in brain cells’ electrical activity.

          advertisement

          Finding so-called biomarkers, or objective measurements reflecting depression, could help diagnose depression, track its progression, predict a relapse, and better tailor therapies to individual patients. But finding those metrics has been difficult, partly because depression’s biological impact isn’t well understood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          Why Medicare shouldn’t cover every FDA
          Why Medicare shouldn’t cover every FDA

          AdobeWhoamongusislookingforwardtogettingolderin2024?Notsenators(mostofwhomare65andolder),thetwoleadi

          read more
          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more

          Readout Newsletter: The latest on Novavax, Merck, Bluebird

          JUSTINTALLIS/AFPviaGettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signuptoget